540 related articles for article (PubMed ID: 12235266)
21. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
23. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
24. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
25. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
[TBL] [Abstract][Full Text] [Related]
26. A role for spinal, but not supraspinal, alpha(2) adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic.
Svokos K; Nalwalk JW; Leurs R; Menge WM; Timmerman H; Hough LB
Brain Res; 2001 Dec; 923(1-2):12-9. PubMed ID: 11743967
[TBL] [Abstract][Full Text] [Related]
27. CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats.
Tseng AH; Craft RM
Psychopharmacology (Berl); 2004 Feb; 172(1):25-30. PubMed ID: 14991224
[TBL] [Abstract][Full Text] [Related]
28. Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic.
Hough LB; Nalwalk JW; Lu Q; Shan Z; Svokos K; Wentland MP; Montero MJ
Eur J Pharmacol; 2005 Oct; 522(1-3):38-46. PubMed ID: 16216240
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
Ihenetu K; Molleman A; Parsons ME; Whelan CJ
Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
[TBL] [Abstract][Full Text] [Related]
30. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice.
Hough LB; Nalwalk JW; Chen Y; Schuller A; Zhu Y; Zhang J; Menge WM; Leurs R; Timmerman H; Pintar JE
Brain Res; 2000 Oct; 880(1-2):102-8. PubMed ID: 11032994
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.
Mato S; Pazos A; Valdizán EM
Eur J Pharmacol; 2002 May; 443(1-3):43-6. PubMed ID: 12044790
[TBL] [Abstract][Full Text] [Related]
32. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
33. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys.
Winsauer PJ; Lambert P; Moerschbaecher JM
Behav Pharmacol; 1999 Sep; 10(5):497-511. PubMed ID: 10780256
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse.
Wallmichrath I; Szabo B
Neuroscience; 2002; 113(3):671-82. PubMed ID: 12150787
[TBL] [Abstract][Full Text] [Related]
36. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
37. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
[TBL] [Abstract][Full Text] [Related]
38. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat.
Scott DA; Wright CE; Angus JA
Pain; 2004 May; 109(1-2):124-31. PubMed ID: 15082134
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
40. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]